Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press86410.17650/1726-9776-2018-14-3-143-148CONGRESSES AND CONFERENCESСЪЕЗДЫ И КОНФЕРЕНЦИИREVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETINGОБЗОР ОНКОУРОЛОГИЧЕСКИХ МАТЕРИАЛОВ КОНГРЕССА АМЕРИКАНСКОГО ОБЩЕСТВА КЛИНИЧЕСКОЙ ОНКОЛОГИИ (ASCO) 2018 Г.https://orcid.org/0000-0002-3672-2369KirichekA. A.КиричекА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

Киричек Андрей Андреевич - аспирант урологического отделения.

115478 Москва, Каширское шоссе, 24.

akirdoctor@gmail.comhttps://orcid.org/0000-0003-0010-6043KamolovB. Sh.КамоловБ. Ш.
Russian Federation

35 Shchepkina St., Moscow 129090.

Камолов Баходур Шарифович - руководитель урологической клиники.

129090 Москва, ул. Щепкина, 35.

kamolov@mail.ruhttps://orcid.org/0000-0001-7748-9527MatveevV. B.МатвеевВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

Матвеев Всеволод Борисович - заместитель директора по инновационной и научной деятельности.

115478 Москва, Каширское шоссе, 24.

vsevolodmatveev@mail.ruNazranovB. M.НазрановБ. М.
Russian Federation

7 Golovko St., Nalchik 360004, Kabardino-Balkar Republic.

Кабардино-Балкарская республика, 360004 Нальчик, ул. Головко, 7.

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииEuropean Medical CenterАО «Европейский медицинский центр»City Clinical Hospital No. 1ГБУЗ «Городская клиническая больница № 1»300920181431431482908201802092018https://oncourology.abvpress.ru/oncur/article/view/864

The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the Annual Meeting proceedings. In this article, a review of the most significant reports on cancer urology from the ASCO 2018 Annual Meeting is presented.

С 1 по 5 июня 2018 г. в Чикаго (США) состоялся 54-й ежегодный конгресс Американского общества клинической онкологии (ASCO) с участием более 40 700 специалистов. Онкоурологические темы составили значительную долю материалов конгресса. В настоящей статье представлен обзор наиболее значимых докладов по онкоурологическим заболеваниям, обсуждавшихся на конгрессе ASCO.

68Ga-PSMA-11 PET/CTAR-V7olaparibabirateroneimmunotherapycancer vaccinesbreakthrough therapyПЭТ/КТ с 68Ga-ПСМА-11AR-V7олапарибабиратерониммунотерапияпротивоопухолевая вакцинапрорывная терапияCastello A., Macapinlac H.A., Lopci E. et al. Prostate-specific antigen flare in-duced by 223RaCl2 in patients with meta-static castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018 May 21 (in press). DOI: 10.1007/s00259-018-4051-y. PMID: 29785515.Castello A., Macapinlac H.A., Lopci E. et al. Prostate-specific antigen flare in-duced by 223RaCl2 in patients with meta-static castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018 May 21 (in press). DOI: 10.1007/s00259-018-4051-y. PMID: 29785515.Clarke N., Wiechno P., Alekseev B. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975–86. DOI: 10.1016/S1470-2045(18)30365-6. PMID: 29880291.Clarke N., Wiechno P., Alekseev B. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975–86. DOI: 10.1016/S1470-2045(18)30365-6. PMID: 29880291.Hansen A.R., Massard C., Ott P.A. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29(8):1807–13. DOI: 10.1093/annonc/mdy232. PMID: 29992241.Hansen A.R., Massard C., Ott P.A. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29(8):1807–13. DOI: 10.1093/annonc/mdy232. PMID: 29992241.McNeel D.G., Eickhoff J.C., Wargowski E. et al. Concurrent, but not sequential, PD-blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2018;9(39):25586–96. DOI: 10.18632/oncotarget.25387. PMID: 29876010.McDermott D., Lee Ja.L., Szczylik C. et al. Pembrolizumab monotherapy as firstline therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 2018;S15:4500. DOI: 10.1200/JCO.2018.36.15_suppl.4500.McDermott D., Lee Ja.L., Szczylik C. et al. Pembrolizumab monotherapy as firstline therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 2018;S15:4500. DOI: 10.1200/JCO.2018.36.15_suppl.4500.McDermott D., Huseni M.A., Atkins M.B. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24(6):749–57. DOI: 10.1038/s41591-018-0053-3. PMID: 29867230.McDermott D., Huseni M.A., Atkins M.B. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24(6):749–57. DOI: 10.1038/s41591-018-0053-3. PMID: 29867230.Powles T., Duran I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI: 10.1016/S0140-6736(17)33297-X. PMID: 29268948.Li Q., Baqrodia A., Cha E.K. et al. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr Urol Rep 2016;17(2):12. DOI: 10.1007/s11934-015-0566-y.Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.